临床IA期纯实性非小细胞肺癌肺门淋巴结转移的预测因素与模式
本研究纳入2009至2023年693例临床IA期纯实性非小细胞肺癌行肺叶切除加肺门淋巴结清扫的患者,评估肺门淋巴结(HLN)及非相邻叶间淋巴结(non-aiLN)转移的频率及预测因素。结果显示HLN转移110例(15.9%),non-aiLN转移34例(4.9%);多因素分析确定CEA水平、左侧、SUVmax和腺癌为HLN转移的独立预测因素。在SUVmax>5.0且CEA>5.0 ng/mL的肿瘤中,HLN转移频率增至23.0%(28/122),其中9例(32.1%)存在non-aiLN转移。结论提示此类患者行肺段切除时应谨慎清扫HLN。
要点
- 临床IA期纯实性NSCLC中HLN转移率15.9%,non-aiLN转移率4.9%。
- CEA升高、左侧、SUVmax升高和腺癌是HLN转移的独立预测因素。
- SUVmax>5.0且CEA>5.0 ng/mL时HLN转移率达23.0%,non-aiLN转移占32.1%。
核心结论
- 临床IA期纯实性NSCLC中HLN和non-aiLN转移较常见,尤其在高SUVmax和高CEA患者中。
- 对SUVmax和CEA均高的临床IA期纯实性NSCLC患者,肺段切除时应仔细清扫HLN。
研究设计与样本
- 回顾性队列研究,纳入2009至2023年693例临床IA期纯实性NSCLC行肺叶切除加HLN清扫的连续患者。
- 采用多因素logistic回归分析评估HLN转移的预测因素。
主要发现
- HLN转移110例(15.9%),non-aiLN转移34例(4.9%)。
- 多因素分析显示CEA水平(P<.01)、左侧(P=.04)、SUVmax(P<.01)和腺癌(P<.01)为HLN转移的独立预测因素。
- SUVmax>5.0且CEA>5.0 ng/mL的肿瘤中,HLN转移频率为23.0%(28/122),其中9例(32.1%)有non-aiLN转移。
关键数值与推荐
- HLN转移独立预测因素:CEA水平(P<.01)、左侧(P=.04)、SUVmax(P<.01)、腺癌(P<.01)。
- SUVmax>5.0且CEA>5.0 ng/mL时HLN转移率23.0%(28/122),non-aiLN转移率32.1%(9/28)。
临床怎么用
- 对临床IA期纯实性NSCLC患者,若SUVmax>5.0且CEA>5.0 ng/mL,肺段切除时应谨慎进行HLN清扫。
- 术前评估CEA、SUVmax、肿瘤侧别和组织学类型有助于预测HLN转移风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Segmentectomy for radiologically pure-solid non-small-cell lung cancer remains controversial due to the high rate of occult lymph node metastasis. Certain hilar lymph nodes (HLN) can be challenging to resect during segmentectomy, especially non-adjacent interlobar lymph node (non-aiLN) distant from the primary tumour. We aimed to elucidate whether HLN metastasis can be predicted more accurately in clinical stage IA pure-solid tumours. METHODS: Between 2009 and 2023, 693 consecutive patients with clinical stage IA pure-solid tumours who underwent lobectomy with HLN dissection were included. The frequencies of HLN and non-aiLN metastases were evaluated. Predictors of HLN metastasis were assessed using multivariable logistic regression analysis. RESULTS: HLN and non-aiLN metastases were detected in 110 (15.9%) and 34 patients (4.9%), respectively. Multivariable logistic regression analysis revealed that carcinoembryonic antigen (CEA) level (P < .01), left side (P = .04), maximum standardized uptake value (SUVmax) (P < .01), and adenocarcinoma (P < .01) were independent predictors of HLN metastasis. Furthermore, in tumours with high SUVmax >5.0 and CEA >5.0 ng/mL, based on the results of the multivariable logistic regression model, the frequency of HLN metastasis increased to 23.0% (28/122). Additionally, 9 (32.1%) tumours had non-aiLN metastases. CONCLUSIONS: HLN and non-aiLN metastases were frequent among clinical stage IA pure-solid tumours, especially in those with SUVmax >5.0 and CEA >5.0 ng/mL. HLN dissection during segmentectomy should be performed carefully in patients with clinical stage IA pure-solid tumours with high SUVmax and CEA.
引用
- Niimi T, Hattori A, Fukui M, et al. Predictors and Patterns of Hilar Lymph Node Metastasis by Tumour Location in Clinical Stage IA Pure-solid Non-small-cell Lung Cancer. Eur J Cardiothorac Surg. 2025. PMID: 41143684. doi:10.1093/ejcts/ezaf361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。